Henkel acquires stake in biotechnology company
After Vermicon, Natural Implant is the second biotechnology company in which Henkel has taken a minority shareholding. Natural Implant has expertise in tissue engineering, i.e. the possibility of growing complex three dimensional human tissues such as skin. "This investment provides an excellent opportunity to utilize Natural Implant's technology for our own research," comments Dr. Wolfgang Gawrisch, Corporate Vice President Research/Technology at Henkel. "Natural Implant's competence in tissue engineering further enhances our biotechnology activities." Henkel's intention is to reinforce its activities in biotechnology through cell culturing in order to make consumer products even more effective and safer. Beyond this, Natural Implant's competence opens up new perspectives for product innovations in important markets. The commitment to biotechnology and positioning as a competent partner and investor is a strategic decision pro innovation and growth.
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.